Dako enters collaboration with Eli Lilly and Company for

Dako enters collaboration with Eli Lilly and Company for development
of companion diagnostics 
GLOSTRUP, DENMARK -- (Marketwire) -- 01/07/13 --  Dako, an Agilent
Technologies company, announced today it has entered into a master
framework agreement with Eli Lilly
and Company for the development of
companion diagnostic tests to identify patients who may be more
likely to benefit from an investigational oncology medicine currently
under development by Lilly. 
The agreement constitutes a framework for collaboration between Dako
and Lilly
with a focus on the Lilly oncology pipeline. 
"Building lasting partnerships is a cornerstone to Dako," says Lars
Holmkvist,
CEO of Dako and senior vice president, Agilent.  "I warmly
welcome Lilly, and I am excited about what we may accomplish together
for the benefit of patients
worldwide. This agreement heralds our
mutual commitment to fighting cancer." 
Companion diagnostics are increasingly in demand with the recognition
that personalized medicine may provide a way to improve patient care
and manage health-care costs by targeting treatments to individuals
more likely to benefit
from specific therapies. 
"Tailored therapies are a key component of Lilly's strategy of
providing improved outcomes for individual patients," says Greg
Zdechlik, chief operating
officer, Diagnostics, Eli Lilly and
Company. "We look forward to collaborating
with Dako in an effort to
develop oncology companion diagnostics for patients
worldwide who are
waiting." 
Dako has a strong heritage of developing diagnostic tests in
collaboration with
pharmaceutical companies. The collaboration with
Lilly is another example of
Dako's position in the clinical
diagnostics market as a strong partner for developing diagnostic
tests for use in conjunction with medicines. 
About Dako - An Agilent Technologies Company 
Dako, based in Denmark, is a global leader in tissue-based cancer
diagnostics.
Hospital and research laboratories worldwide use Dako's
reagents, instruments,
software and expertise to make accurate
diagnoses and determine the most effective treatment for cancer
patients. Dako, with 1,200 employees, operates in more than 100
countries. Dako became part of Agilent Technologies on June 21, 2012.
Information about Dako is available at www.dako.com. 
About Agilent Technologies 
Agilent Technologies Inc. (NYSE: A) is the world's premier
measurement company
and a technology leader in chemical analysis, life
sciences, diagnostics, electronics and communications. The company's
20,500 employees serve customers
in more than 100 countries. Agilent
had revenues of $6.9 billion in fiscal 2012. Information about
Agilent is available at www.agilent.com. 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Dako Denmark A/S via Thomson Reuters ONE 
[HUG#1668620] 
EDITORIAL CONTACT: 
Maia Fredtoft Sochting
Dako
+45 25 46 10 83
maia.sochting@dako.com